Novavax studies COVID-19 vaccine was 90% efficient in Phase 3 examine

Novavax studies COVID-19 vaccine was 90% efficient in Phase 3 examine


Novavax
NVAX,
+2.31%

reported {that a} Phase 3 examine of its COVID-19 vaccine confirmed it was 90.4% efficient general. The 29,960-patient examine additionally discovered that the vaccine offered 100% safety in opposition to average and extreme illness. The firm intends to file for regulatory authorizations within the third quarter, and it stated it stays on observe to achieve manufacturing capability of 100 million doses monthly by the top of the third quarter and 150 million doses monthly by the top of the fourth quarter of 2021. Shares within the Gaithersburg, Md. firm jumped 8% in premarket commerce.



Source link

Business